Platelet-Activating Factor (PAF) Receptor Antagonism Modulates Inflammatory Signaling in Experimental Uveitis
- 11 April 2018
- journal article
- research article
- Published by Taylor & Francis in Current Eye Research
- Vol. 43 (6) , 821-827
Abstract
Background: The phospholipid mediator platelet-activating factor (PAF) activates an inflammatory response that includes arachidonic acid release and prostaglandin production in the eye, increasing vascular permeability and inflammation. The purpose of this study is to investigate the action of LAU-0901, a novel PAF receptor antagonist, on experimental uveitis. Methods: Uveitis was induced in Lewis rats by lipopolysaccharide treatment. LAU-0901 was then delivered systemically in different concentrations at plus 4 and 16 hours, or vehicle injected as controls. Additional animals were used for histological analyses of untreated, uveitis, and uveitis-plus-LAU-0901 retinas. Conventional histological and immunohistochemical methods were employed. A slit lamp and Spectral Domain-Ocular Coherence Tomography (SD-OCT) retinal imager was used for anterior segment photography and posterior pole OCT. Rats were euthanized 4 hours after the second LAU-0901 injection in this 24-hour model. Aqueous humor was collected and quantified, and also analyzed for tumor necrosis factor alpha (TNF-α). Results: Uveitic eyes demonstrated hypopyon formation, leukocyte infiltration, and an increase in aqueous protein and TNF-α levels. LAU-0901 treatment resulted in a dose-dependent reduction in inflammation, reflected by reduced total protein levels (up to a 64% reduction). Moreover, hypopyon was prevented, leukocytes were absent in vitreous and aqueous humor, and TNF-α levels were reduced by 91%. Conclusions: The PAF receptor antagonist LAU-0901 decreases ocular inflammation in a rat model of anterior uveitis in a dose-dependent manner, suggesting that use of this molecule may provide a means to attenuate inflammation onset and offer a future alternative or adjunctive treatment for ocular inflammation.Keywords
Funding Information
- National Eye Institute (EY005121)
- National Institute of General Medical Sciences (GM103340)
This publication has 28 references indexed in Scilit:
- A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal FibrosisPLOS ONE, 2013
- Ocular actions of platelet-activating factor: clinical implicationsExpert Opinion on Therapeutic Targets, 2012
- Noninvasive molecular imaging reveals role of PAF in leukocyte‐endothelial interaction in LPS‐induced ocular vascular injuryThe FASEB Journal, 2011
- Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1Journal of Lipid Research, 2010
- LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the ratBrain Research, 2009
- LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemiaExperimental Neurology, 2008
- Leukocyte Diapedesis In Vivo Induces Transient Loss of Tight Junction Protein at the Blood–Retina BarrierInvestigative Ophthalmology & Visual Science, 2005
- Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expressionEuropean Journal of Cell Biology, 2000
- Ginkgo biloba extract (EGb 761) and a platelet-activating factor antagonist protect the retina in experimental autoimmune uveoretinitisOcular Immunology and Inflammation, 1994
- Prolonged effect of a new platelet-activating factor antagonist on ocular vascular permeability in an endotoxin model of uveitisCurrent Eye Research, 1991